Liposomes as a Drug Delivery System for Antisense Oligonucleotides

Antisense Research and Development

Volumn 2, Issue 2, 1992, Pages 165-176

  Juliano, R L ^a   Akhtar, Saghir ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DRUG CARRIER; LIPOSOME;

CELL NUCLEUS; CYTOPLASM; DRUG STABILITY; HUMAN; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CYTOPLASM; DRUG CARRIERS; DRUG STABILITY; HUMAN; LIPOSOMES; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0026877363     PISSN: 10505261     EISSN: 15578526     Source Type: Journal    
DOI: 10.1089/ard.1992.2.165     Document Type: Article

References (76)

1. ABRA, R.M., and HUNT, C.A. (1981). Liposome disposition in vivo III: dose and vesicle size effects. Biochim. Biophys. Acta 666, 493–503.
2. AGRAWAL, S., IKEUCHI, T., SUN, D., SARIN, P.S., KONOPKA, A., MAIZEL, J., and ZAMECNIK, P.C. (1989). Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA 86, 7790–7794.
3. AKHTAR, S., and JULIANO, R.L. (1991). Antisense DNA oligonucleotides as potential therapeutic agents. Pharm. J. 247,89–92.
4. AKHTAR, S., and JULIANO, R.L. (1992). Liposome delivery of antisense oligonucleotides: adsorption and efflux characteristics of phosphorothioate oligonucleotides. J. Cont. Rel. (in press).
5. AKHTAR, S., BASU, S., WICKSTROM, E., and JULIANO, R.L. (1991b). Permeation characteristics of antisense DNA oligonucleotide analogs across model membranes (liposomes). Nucleic Acids Res. 19, 5551–5559.
6. AKHTAR, S., KOLE, R., and JULIANO, R.L. (1991a). Stability of modified antisense oligodeoxynucleotides in cellular extracts and sera. Life Sci. 49, 1793–1801.
7. ALLEN, T.M., HANSEN, C., and RUTLEDGE, J. (1989). Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 981, 27–35.
8. ALLEN, T.M., HANSEN, C., MARTIN, F., REDEMANN, C., and YAU-YOUNG, A. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta Bio-Membr. 1066, 29–36.
9. ALTURA, D.N., and SABA, T.M. (1981). Pathophysiology of the Reticuloendothelial System. (Raven Press, New York).
10. ALVING,C.R. (1988). Macrophages as targets of liposome-encapsulated antimicrobial agents. Adv. Drug Delivery Rev. 2, 107–128.
11. BECKER, S. (1988). Functions of the human mononuclear phagocyte system-a condensed review. Adv. Drug Delivery Rev. 2, 1–30.
12. BONTE, F., and JULIANO, R.L. (1986). Interaction of liposomes with serum proteins. Chem. Phys. Lipids 40, 359–372.
13. BYRN, S.R., CARLSON, D.V., CHEN, J.K., CUSHMAN, M.S., GOLDMAN, M.E., MA, W.P., PIDGEON, C.L., RAY,K.A.,STOWELL,J.E.,and WEITH,H.L. (1991). Drug oligonucleotide conjugates. Adv. Drug Delivery Rev. 6, 287–308.
14. CHIN, D.J., GREEN, G.G., ZON, G., SZOKA, F.C. and STRAUBINGER, R.M. (1990). Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biologist 2, 1091–1110.
15. CHU, C.J., DIJKSTRA, J., HONG, K., LAI, M., and SZOKA, F. (1990). Efficiency of cytoplasmic delivery by pH sensitive liposomes to cells in culture. Pharmaceutical Res. 7, 824–834.
16. COHEN, J.S. (1989). Designing antisense oligonucleotides as pharmaceutical agents. Trends Pharmacol Sci. 10, 435–437.
17. CULLIS, P.R., MAYER, L.D., BALLY, M.B., MADDEN, T.D. and HOPE, M.J. (1989). Generating and loading of liposomal systems for drug-delivery applications. Adv. Drug Delivery Rev. 3, 267–282.
18. CYNAMON, M.H., SWENSON, C.E., PALMER, G.S., and GINSBERG, R.S. (1989). Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 33, 1179–1183.
19. DUZGUNES, N., ASHTEKAR, D.R., FLASHER, D.L., GHORI, N., DEBS, R.J., FRIEND, D.S., and GANGADHARAM, P.R. (1991). Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J. Infect. Dis. 164, 143–151.
20. ECKSTEIN, F. (1985). Nucleoside phosphorothiates. Annu. Rev. Biochem. 54, 367–402.
21. FELGNER, P.L. (1990). Particulate systems for in vitro and in vivo delivery of polynucleotides. Adv. Drug Delivery Rev. 5, 163–188.
22. FELGNER, P.L., and RINGOLD, G.M. (1989). Cationic liposome mediated transfection. Nature 337, 387–388.
23. FIDLER, I.J. (1988). Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Delivery Rev. 2, 69–106.
24. FIDLER, I.J., and BALCH, C.M. (1987). The biology of cancer metastasis and implications for therapy. Curr. Prob. Surg. 24, 129–209.
25. FURDON, P.J., DOMINSKI, Z., and KOLE, R. (1989). RNaseH cleavage of RNA hybridized to oligonucleotides with methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17, 9193–9204.
26. GABIZON, A., and PAPAHADJOPOULOS, D. (1988). Liposome formulations with prolongedciruclation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85, 6949–6953.
27. GABIZON, A., PRICE, D.C., HUBERTY, J., BRESALIER, R.S., and PAPAHADJOPOULOS, D. (1990). Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50, 6371–6378.
28. GEWIRTZ, A.M., and CALABRETTA, B. (1988). A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242, 1303–1306.
29. HELENE, C., and TOULME, J.J. (1990). Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049, 99–125.
30. HOPE, M.J., BALLY, M.B., WEBB, G., and CULLIS, P.R. (1985). Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812, 55–65.
31. HSU, M.J., and JULIANO, R.L. (1982). Interactions of liposomes with the reticuloendothelial system II: nonspecific and receptor mediated uptake of liposomes by mouse peritoneal macrophages. Biochim. Biophys. Acta. 720, 411–419.
32. HUANG, A., KENNEL, S.J., and HUANG, L. (1983). Interactions of immunoliposomes with target cells. J. Biol. Chem. 258, 14034–14404.
33. HWANG, K.J. (1987). Liposome pharmacokinetics. In Liposomes: From Biophysics to Therapeutics, M.J. Ostro, ed. (Marcel Dekker, New York), pp. 109–156.
34. Jain, M.K. (1988). Introduction to Biological Membranes. (Wiley, New York).
35. JAROSZEWSKI, J.W., and COHEN, J.S. (1991). Cellular uptake of antisense oligonucleotides. Adv. Drug Delivery Rev. 6, 235–250.
36. JULIANO, R.L. (1988). Factors controlling the kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Delivery Rev. 2, 31–54.
37. JULIANO, R.L. (1989). Liposomes as drug carriers in therapy of infectious disease. Horizons Biochem. Biophys. 9, 249–280.
38. JULIANO, R.L. (ed.) (1991). Targeted Drug Delivery, vol. 100. Handbook of Experimental Pharmacology (Springer Verlag, Heidelberg).
39. JULIANO, R.L., and STAMP, D. (1975). Effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochim. Biophys. Res. Commun. 63, 651–658.
40. JULIANO, R.L., GRANT, C.W.M., BARBER, K.R., and KALP, M.A. (1987). Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Molec. Pharmacol. 31, 1–11.
41. KAO, Y.J., and JULIANO, R.L. (1981). Interactions of liposomes with the reticuloendothelial system. Effects of blockade on the clearance of large unilamellar vesicles. Biochim. Biophys. Acta 677, 453–461.
42. KLIBANOV, A.L., MARUYAMA, K., TORCHILIN, V.P., and HUANG, L. (1990). Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235–237.
43. KOTYK, A. (1985). Basic kinetics of membrane transport. In Structure and Properties of Cell Membranes, G. Banga,ed.(CRC Press, Boca Raton, Florida).
44. LEONETTI, J.P., MACHY, P., DEGOLS, G., LEBLEU, B., and LESERMAN, L. (1990). Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Natl. Acad. Sci. USA 87, 2448–2451.
45. LEONETTI, J.P., MECHTI, N., DEGOLS, G., GAGNOR, C., and LEBLEU, B. (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88, 2702–2706.
46. LESERMAN, L., MACHY, P. and BARBET, J. (1981). Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature 293, 226–228.
47. LOKE, S.L., STEIN, C.A., ZHANG, X.H., MORI, K., NAKANISHI, M., SUBASINGHE, B., COHEN, J.S., and NECKER, I.M. (1989). Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci. USA 86, 3474–3478.
48. MATSUKURA, M., SHINOZUKA, K., ZON, G., MITSUYA, H., REITZ, M., COHEN. J.S., and BRODER, S. (1987). Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84, 7706–7710.
49. McMANAWAY, M.E., NECKERS, L.M., LOKE, S.L., AL-NASSER, A.A., REDNER, R.L., SHIRAMIZU, B.T., GOLDSCHMIDTS, W.L., HUBER, B.E., BHATIA, K. and MAGRATH, I.T. (1990). Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 335, 808–811.
50. MERRILL, J.E., and CHEN, I.S. (1991). HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J. 5, 2391–2397.
51. MILLER, P.S., DREON, N., PULFORD, S.M., and McPARLAND, K.B. (1980). Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phosphodiester backbones. J. Biol. Chem. 255, 9659–9665.
52. MILLER, P.S.,McFARLAND,K.B., JAYARAMAN,K., and TS'O P.O.P. (1981). Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20, 1874–1880.
53. MORGAN, J.R., WILLIAMS, L.A., and HOWARD, C.B. (1985). Technetium-labelled liposome imaging for deep-seated infection. Br. J. Radiol. 58, 35–39.
54. NOÈ, C.,HERNANDEZ-BORRELL, J., KINSKY, S.C.,MATSUURA,E., and LESERMAN, L.(1988). Inhibition of cell proliferation with antibody-targeted liposomes containing methotrexate-gamma-dimyristoylphosphatidylethanolamine. Biochim. Biophys. Acta 946, 253–260.
55. OSTRO, M.J. (ed.) (1987). Liposomes: From Biophysics to Therapeutics. (Marcel Dekker, New York).
56. PEREZ-SOLER, R., LOPEZ-BERESTEIN, G., KASI, L.P., CABANILLAS, F., JAHNS, M., GLENN, H., HERSH, E.M., and HAYNIE, T. (1985). Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's Disease. J. Nucl. Med. 26, 743–749.
57. POZNANSKI, M., and JULIANO, R.L. (1984). Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol. Rev. 36, 277–336.
58. RAHMAN, A., TREAT, J., ROH, J.K., POTKUL, L.A., ALVORD, W.G., FORST, D., and WOOLLEY, P.V. (1990). A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol. 8, 1093–1100.
59. SAISON-BEHMOARAS, T., TOCQUÉ, B., REY, I., CHASSIGNOL, M., THUONG, N.T., and HÉLÈNE, C. (1991). Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10, 1111–1118.
60. SCHERPHOF, G., DAMEN, J., and HOEKSTRA, D. (1981). Interactions of liposomes with plasma proteins and components of the immune system. In Liposomes: From Physical Structure to Therapeutic Applications, G. Knight, ed. (Elsevier, Amsterdam), pp. 299–322.
61. SENIOR, J. (1987). Fate and behavior of liposomes in vivo: A review of controlling factors. CRC Crit. Rev. Drug Carrier Systems 32, 123–193.
62. SHOJI, Y., AKHTAR, S., PERIASAMY, A., HERMAN, B., and JULIANO, R.L. (1991). Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19, 5543–5550.
63. SMITH, R.D. (1990). The pathobiology of HIV infection. A review. Arch. Pathol. Lab. Med. 114, 235–239.
64. STEIN, C.A., MORI, K., HOKE, S.H., SUBUSINSHE, C., SHINUZUKA, K., COHEN, J.S., and NECKERS, M. (1988). Phosphorthioate and normal oligonucleotides with 5′ linked acridine: characterization and preliminary kinetics of cellular uptake. Gene 72, 333–341.
65. STRAUBINGER, R.M., HONG, K., FRIEND, D.S., and PAPAHADJOPOULOS, D. (1983). Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell 32, 1069–1079.
66. STRAUBINGER, R.M., LOPEZ, N.G., DEBS, R.J., HONG, K., and PAPAHADJOPOULOS, D. (1988). Liposomebased therapy of human ovarian cancer: Parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 48, 5237–5245.
67. SZOKA, F., and PAPAHADJOPOULOS, D. (1980). Comparative properties and methods in preparation of lipid vesicles. Annu. Rev. Biophys. Bioeng. 9, 467–508.
68. TOMLINSON, E. (1987). Theory and practice of site-specific drug delivery. Adv. Drug Delivery Rev. 1, 87–108.
69. TURNER, A.F., PRESANT, C.A., PROFFITT, R.T., WILLIAMS, L.E., and WINSOR, J.L. (1988). III. Liposomes: Dosimetry and tumor depictions. Radiology 166, 761–765.
70. WANG, C.Y., and HUANG, L. (1987a). Plasmid DNA adsorbed to pH sensitive liposomes efficiently transforms target cells. Biochem. Biophys. Res. Comm. 147, 980–985.
71. WANG, C.Y., and HUANG, L. (1987b). pH sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc. Natl. Acad. Sci. USA 84, 7851–7855.
72. WANG, C.Y., and HUANG, L. (1989). Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. Biochemistry 28, 9508–9514.
73. WICKSTROM, R. (1986). Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Meth. 13, 97–102.
74. WRIGHT, S., and HUANG, L. (1989). Antibody directed liposomes as drug delivery vehicles. Adv. Drug Delivery Rev. 3, 343–390.
75. YAKUBOV, L.A., DEEVA, E.A., ZARYTOVA, V.F., IVANOVA, E.M., RYTE, A.J., YURCHENKO, L.V., and VLASSOV, V.V. (1989). Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors. Proc. Natl. Acad. Sci. USA 86, 6454–6458.
76. ZON, G. (1988). Oligonucleotides as potential therapeutic agents. Pharmaceut. Res. 5, 539–548.